NuCana plc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.0M
- Price
- $1.09
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.83%
- Volume
- 51.0K
About
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Quick stats
Shares outstanding4.6M
Computed float4.6M
Float / shares100.0%
Cash runway (months)19.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001709626
Websitehttps://www.nucana.com
AI Summary
AI-generated1/4
minorbullishother
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
NuCana announced the European Patent Office granted a composition-of-matter patent (EP 3683225) covering the chemical structure of NUC-7738, its lead anti-cancer agent.
NUC-7738 is now protected by over 85 issued patents worldwide and is in the Phase 2 portion of the Phase 1/2 NuTide:701 study in combination with Keytruda for PD-1 inhibitor-resistant metastatic melanoma.
Management said cash resources are expected to fund planned operations into 2029, positioning the company to hit further clinical milestones through the rest of 2026.